Furthermore, these CAR-Ts demonstrated robust antileukemic activity in in vitro cytotoxicity assays on CD7-proficient cell lines (including Jurkat, Loucy, MOLT-4, KG1a, and CCRF-CEM) and in vivo assessments in cell line-established and patient-derived xenografts (PDX) models of T-ALL [58]. This evidence concerns the gene CD7 and acute lymphoblastic leukemia.